2 recruiting, 2 terminated, 2 unknown, 1 completed. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 2, Terminated 2, Unknown 2, Completed 1 |
| Phase 2 | 4 | Completed 1, Recruiting 1, Terminated 1, Unknown 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors EOS006215, Anticancer agent - Selected Advanced Solid Tumors | Phase 1 | Terminated | iTeos Belgium SA | 3 | 2025-04-07 | 2025-08-12 |
| A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors BG-C137, Anticancer Agents - Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 168 | 2024-12-09 | 2026-07-09 |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer Parimparib, Chemotherapy drug, Targeted Therapy Agent - Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer | Phase 1 | Unknown | Affiliated Hospital of Jiangnan University | 40 | 2022-12-20 | 2024-01-31 |
| A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients Plasma soluble TNF receptor pulldown, Plasma soluble TNF receptor pulldown + chemotherapy, Chemotherapy Drugs, Cancer - Advanced Breast Cancer | Phase 1 / Phase 2 | Unknown | Immunicom Inc | 170 | 2019-05-31 | 2022-03-24 |
| Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer Chemotherapy Drugs, Cancer - Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Shaare Zedek Medical Center | 15 | 2019-04-18 | 2020-10-23 |
| Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) Idarubicin, Cytarabine, Lenalidomide (Revlimid®) - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 51 | 2009-06-25 | 2020-12-22 |
| ABT-751 With Chemotherapy for Relapsed Pediatric ALL ABT-751, Dexamethasone, PEG-asparaginase - Recurrent Pediatric ALL, Relapsed Pediatric ALL | Phase 1 / Phase 2 | Terminated | Therapeutic Advances in Childhood Leukemia Consortium | 9 | 2006-05-22 | 2021-03-17 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Affiliated Hospital of Jiangnan University (1) · BeOne Medicines (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Immunicom Inc (1) · Shaare Zedek Medical Center (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · iTeos Belgium SA (1)
United States (4) · China (2) · Australia (1) · Israel (1) · Poland (1) · South Korea (1) · Turkey (Türkiye) (1)
Adam Ostrowski, MD (1) · Alberto A Gabizon, MD, PhD (1) · Jeffrey Lancet, M.D. (1) · Paul S Gaynon, MD (1)
PMID 14998846, PMID 25415656, PMID 26408258, PMID 27912846, PMID 42361329
2025 (1)